Solutions & Models
Delivery models, workforce plans, payment bundles, registries, training, and practical ways to make psychedelic therapy easier to implement.
Implementation needs workable models, not only good intentions. The field has to decide how care is staffed, paid for, monitored, referred into, and improved over time.
Some solutions reduce delivery burden, such as group formats, shorter protocols, task-sharing, digital support, registry-based follow-up, or clearer credentialing. Others help payers manage uncertainty through staged access or outcomes tracking.
Use this section to compare the models that could turn a therapy from a specialist experiment into a governed clinical service.
Guides and tools
PsyPal 2026: What the guidance changes for implementation strategy
A practical synthesis of the 2026 PsyPal guidance for psychedelic therapy implementation, access planning, service design, and payer readiness.
Potential Reimbursement and Access Pathways
Nine routes that could shape psychedelic therapy access, from ordinary reimbursement to pilots, private payment, special access, and managed entry.
Solutions and Recommendations
Practical recommendations for evidence generation, payment design, regulation, delivery infrastructure, and equitable access.
Netherlands Psilocybin Access Sites
A map of current Dutch COMP006 trial sites and plausible implementation infrastructure for a future psilocybin-assisted treatment pathway.
Netherlands Psychedelic Therapy Workforce
A Dutch workforce-readiness page and scenario model for turning BIG-registered professionals into practical psychedelic-therapy capacity.
Psychedelic Therapy Launch-Readiness Checklist
A practical Road to Access checklist for turning a positive clinical and regulatory path into reimbursed, governed, and deliverable psychedelic-assisted therapy.
Clinical Delivery Model for Psychedelic Therapy
A governed clinical pathway for psychedelic therapy, from referral and screening through dosing-day care, follow-up, escalation, and outcome reporting.
Referral, Screening, and Triage Pathway
A patient-entry pathway showing how someone can be referred, screened, treated, deferred, redirected, or followed after psychedelic therapy.
Training and Credentialing for Psychedelic Therapy
A governance resource separating training, credentialing, supervision, fidelity monitoring, professional authorization, and site accountability.
Further reading
Oregon Psilocybin Services
access programme source relevant to solutions & models.
Oregon Health Authority | 2 Jan 2023 | US | Access Programme | Reviewed 17 Apr 2026
Special Access Program for Drugs
access programme source relevant to solutions & models.
Health Canada | 8 Apr 2026 | Canada | Access Programme | Reviewed 17 Apr 2026
Notice to stakeholders: Requests to the Special Access Program involving psychedelic-assisted psychotherapy
guidance source relevant to solutions & models.
Health Canada | 27 Feb 2023 | Canada | Guidance | Reviewed 17 Apr 2026
Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists
framework source relevant to solutions & models.
Therapeutic Goods Administration (Australia) | 3 Feb 2023 | Australia | Framework | Reviewed 17 Apr 2026
Ketamine TRD ? Interventional Psychiatry Service
Service-level implementation example for treatment-resistant depression pathway delivery.
Oxford Health NHS Foundation Trust | 1 Jan 2024 | UK | Access Programme | Reviewed 17 Apr 2026
MDMA: Beyond Ecstasy
analysis source relevant to solutions & models.
Government of the Netherlands | 31 May 2024 | Netherlands | Analysis | Reviewed 17 Apr 2026